WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
PLANO, Texas, May 03, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the 18th Annual B. Riley Co. Investor Conference in Santa Monica, CA. Management will also be available for one-on-one meetings at the conference.
Event: 18th Annual B. Riley Co. Investor Conference
Format: Presentation and One-on-One Meetings
Date: Wednesday, May 24, 2017
Time: 2:00 pm PT
A webcast of the Company’s presentation will be available on the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the chat will be available for 90 days.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Operating Officer and Chief Financial Officer (214) 474-3102 [email protected] Jennifer Armstrong, Media Relations (214) 474-3110 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
